PHIO Stock Overview
Engages in the development of immuno-oncology therapeutics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Phio Pharmaceuticals Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.89 |
| 52 Week High | US$10.35 |
| 52 Week Low | US$1.53 |
| Beta | 1.53 |
| 1 Month Change | 11.83% |
| 3 Month Change | -35.93% |
| 1 Year Change | -64.32% |
| 3 Year Change | -98.05% |
| 5 Year Change | -99.42% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Phio Pharmaceuticals appoints interim executive chairman
Sep 29Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12
Aug 11Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?
Apr 11
Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer
Nov 09Shareholder Returns
| PHIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.3% | 1.3% | 0.2% |
| 1Y | -64.3% | 0.9% | 22.0% |
Return vs Industry: PHIO underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: PHIO underperformed the US Market which returned 22% over the past year.
Price Volatility
| PHIO volatility | |
|---|---|
| PHIO Average Weekly Movement | 87.1% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PHIO's weekly volatility has increased from 45% to 87% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 9 | Bob Bitterman | phiopharma.com |
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor.
Phio Pharmaceuticals Corp. Fundamentals Summary
| PHIO fundamental statistics | |
|---|---|
| Market cap | US$6.91m |
| Earnings (TTM) | -US$7.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs PHIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$3.67m |
| Gross Profit | -US$3.66m |
| Other Expenses | US$3.75m |
| Earnings | -US$7.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 00:46 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Phio Pharmaceuticals Corp. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Mark Breidenbach | H.C. Wainwright & Co. |
| Vernon Bernardino | H.C. Wainwright & Co. |